{"id":"platinum-investigator-s-choice","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Nephrotoxicity"},{"rate":"5-20","effect":"Ototoxicity"},{"rate":"30-50","effect":"Myelosuppression"},{"rate":"40-80","effect":"Nausea and vomiting"},{"rate":"10-30","effect":"Peripheral neuropathy"},{"rate":"20-40","effect":"Anemia"},{"rate":"15-35","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL2068323","moleculeType":"Small molecule","molecularWeight":"516.24"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Platinum-based chemotherapy agents, such as cisplatin, carboplatin, and oxaliplatin, bind to DNA and form interstrand and intrastrand cross-links. These cross-links prevent DNA replication and transcription, leading to cell cycle arrest and programmed cell death. The term 'investigator's choice' indicates the specific platinum agent is selected by the treating physician based on the clinical context and patient factors.","oneSentence":"Platinum compounds form DNA-damaging adducts that cross-link DNA strands, triggering apoptosis in rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:45.140Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Various solid tumors (specific indication determined by investigator choice in clinical trial)"}]},"trialDetails":[{"nctId":"NCT04092283","phase":"PHASE3","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-29","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":660},{"nctId":"NCT07492342","phase":"PHASE2","title":"Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC","status":"RECRUITING","sponsor":"Jianxing He","startDate":"2026-01-29","conditions":"Resectable NSCLC, KRAS G12C Mutation, Stage IB-IIIA NSCLC","enrollment":30},{"nctId":"NCT06623422","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-10-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":680},{"nctId":"NCT07214779","phase":"PHASE3","title":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-12-09","conditions":"Ovarian Cancer","enrollment":466},{"nctId":"NCT03570892","phase":"PHASE3","title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":"Non-Hodgkin Lymphoma","enrollment":331},{"nctId":"NCT07190248","phase":"PHASE3","title":"A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-10-08","conditions":"Non-small Cell Lung Cancer","enrollment":675},{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT04658862","phase":"PHASE3","title":"A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-12-07","conditions":"Urinary Bladder Neoplasms","enrollment":518},{"nctId":"NCT07286266","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-24","conditions":"Ovarian Neoplasms","enrollment":450},{"nctId":"NCT05789082","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-06-20","conditions":"Non-Small Cell Lung Cancer","enrollment":320},{"nctId":"NCT05635708","phase":"PHASE2","title":"A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-03-07","conditions":"Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer","enrollment":400},{"nctId":"NCT04892173","phase":"PHASE3","title":"JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC","status":"RECRUITING","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","startDate":"2021-12-10","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged","enrollment":500},{"nctId":"NCT04729387","phase":"PHASE3","title":"Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-07-22","conditions":"Ovarian Cancer","enrollment":358},{"nctId":"NCT05061550","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2022-04-14","conditions":"Non-small Cell Lung Cancer","enrollment":630},{"nctId":"NCT06097728","phase":"PHASE3","title":"MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-09","conditions":"Unresectable Pleural Mesothelioma","enrollment":825},{"nctId":"NCT07166094","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer","status":"RECRUITING","sponsor":"Genmab","startDate":"2025-11-28","conditions":"Endometrial Cancer, Recurrent or Progressive Endometrial Cancer","enrollment":544},{"nctId":"NCT06619236","phase":"PHASE3","title":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2025-02-07","conditions":"Platinum-resistant Ovarian Cancer","enrollment":530},{"nctId":"NCT06772623","phase":"PHASE1, PHASE2","title":"Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-03-06","conditions":"Non Small Cell Lung Carcinoma","enrollment":252},{"nctId":"NCT03976323","phase":"PHASE3","title":"Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-28","conditions":"Carcinoma, Nonsquamous Non-small-cell Lung","enrollment":1003},{"nctId":"NCT07419295","phase":"PHASE3","title":"A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)","status":"NOT_YET_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-17","conditions":"Bladder Cancer","enrollment":590},{"nctId":"NCT07418931","phase":"PHASE2","title":"A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2026-05","conditions":"Advanced Squamous Non-Small Cell Lung Cancer","enrollment":108},{"nctId":"NCT07418749","phase":"PHASE3","title":"A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"Recurrent Cervical Cancer, Metastatic Cervical Cancer","enrollment":398},{"nctId":"NCT05715229","phase":"PHASE2","title":"Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2023-09-29","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":108},{"nctId":"NCT03819465","phase":"PHASE1","title":"A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-12-27","conditions":"Metastatic Non-Small Cell Lung Cancer (NSCLC)","enrollment":175},{"nctId":"NCT06557889","phase":"PHASE2","title":"Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2024-10-21","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":86},{"nctId":"NCT04585477","phase":"PHASE2","title":"Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-04-08","conditions":"Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II","enrollment":80},{"nctId":"NCT07392658","phase":"PHASE2","title":"Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.","status":"RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2025-12-02","conditions":"Metastatic NSCLC - Non-Small Cell Lung Cancer","enrollment":33},{"nctId":"NCT07392060","phase":"PHASE3","title":"A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiatan Pharmatech Co., Ltd","startDate":"2026-02-28","conditions":"Cervical Cancer Metastatic","enrollment":440},{"nctId":"NCT06340568","phase":"PHASE3","title":"A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-06-10","conditions":"Endometrial Cancer","enrollment":480},{"nctId":"NCT06564844","phase":"PHASE3","title":"A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-10-15","conditions":"Non-small Cell Lung Cancer","enrollment":24},{"nctId":"NCT07358676","phase":"PHASE2","title":"A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-01","conditions":"Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage","enrollment":25},{"nctId":"NCT06430437","phase":"PHASE3","title":"A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-07-29","conditions":"Non-Small Cell Lung Cancer With HER2- Mutations","enrollment":300},{"nctId":"NCT07218809","phase":"PHASE3","title":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-29","conditions":"Epithelial Ovarian Cancer","enrollment":1100},{"nctId":"NCT07340164","phase":"PHASE2","title":"Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-12-30","conditions":"Ovarian Cancer, Ovarian Carcinoma, Recurrent, Ovarian Cancer Metastatic Recurrent","enrollment":116},{"nctId":"NCT06161025","phase":"PHASE2, PHASE3","title":"A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-02-27","conditions":"Solid Cancer","enrollment":860},{"nctId":"NCT06132958","phase":"PHASE3","title":"Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-06","conditions":"Endometrial Cancer","enrollment":710},{"nctId":"NCT05945823","phase":"PHASE2","title":"Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Taiho Oncology, Inc.","startDate":"2023-07-13","conditions":"Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer","enrollment":53},{"nctId":"NCT06703398","phase":"PHASE2","title":"A Study of GC101 TIL in Advanced Melanoma","status":"RECRUITING","sponsor":"Shanghai Juncell Therapeutics","startDate":"2024-12-20","conditions":"Melanoma","enrollment":98},{"nctId":"NCT05048797","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-28","conditions":"Locally Advanced or Metastatic Non-Small Cell Lung Cancer","enrollment":454},{"nctId":"NCT06855069","phase":"PHASE3","title":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-03-13","conditions":"Ovarian Cancer","enrollment":468},{"nctId":"NCT06281964","phase":"PHASE3","title":"Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.","status":"ENROLLING_BY_INVITATION","sponsor":"Avistone Biotechnology Co., Ltd.","startDate":"2023-12-01","conditions":"Non-Small-Cell Lung Cancer","enrollment":327},{"nctId":"NCT04949256","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-07-28","conditions":"Metastatic Esophageal Squamous Cell Carcinoma","enrollment":864},{"nctId":"NCT03615326","phase":"PHASE3","title":"Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-05","conditions":"Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma","enrollment":738},{"nctId":"NCT02364713","phase":"PHASE2","title":"MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-03-13","conditions":"Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":17},{"nctId":"NCT04428151","phase":"PHASE2","title":"Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":408},{"nctId":"NCT05568212","phase":"PHASE2","title":"Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab","status":"RECRUITING","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2022-05-02","conditions":"Non-small-cell Lung Cancer Patients","enrollment":176},{"nctId":"NCT07244965","phase":"PHASE2","title":"Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Women's Hospital School Of Medicine Zhejiang University","startDate":"2025-12-01","conditions":"LOCALLY ADVANCED CERVICAL CANCERS","enrollment":42},{"nctId":"NCT07230626","phase":"PHASE3","title":"SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-11-20","conditions":"Cervical Cancer","enrollment":412},{"nctId":"NCT04194944","phase":"PHASE3","title":"A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-02-17","conditions":"Non-Small Cell Lung Cancer","enrollment":261},{"nctId":"NCT05613088","phase":"PHASE2","title":"A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-02-01","conditions":"Neoplasms, Ovarian","enrollment":106},{"nctId":"NCT03520686","phase":"PHASE3","title":"Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-18","conditions":"Non Small Cell Lung Cancer","enrollment":1538},{"nctId":"NCT06699212","phase":"PHASE3","title":"A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases","status":"RECRUITING","sponsor":"Rakuten Medical, Inc.","startDate":"2024-12-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":412},{"nctId":"NCT02964013","phase":"PHASE1","title":"Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001) ( KEYVIBE-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-12-13","conditions":"Neoplasms","enrollment":474},{"nctId":"NCT05870748","phase":"PHASE2, PHASE3","title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","status":"TERMINATED","sponsor":"Sutro Biopharma, Inc.","startDate":"2023-07-12","conditions":"Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":600},{"nctId":"NCT06840782","phase":"PHASE3","title":"First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09-09","conditions":"Oligometastatic Non-small Cell Lung Cancer (NSCLC)","enrollment":124},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT05092360","phase":"PHASE3","title":"Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)","status":"TERMINATED","sponsor":"Mural Oncology, Inc","startDate":"2022-01-10","conditions":"Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":456},{"nctId":"NCT03977467","phase":"PHASE2","title":"Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2019-08-30","conditions":"Non-Small Cell Lung Cancer, Solid Tumor","enrollment":46},{"nctId":"NCT04209855","phase":"PHASE3","title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-12-31","conditions":"Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":453},{"nctId":"NCT07138001","phase":"PHASE2","title":"Phase 2 Clinical Trial of KH617","status":"NOT_YET_RECRUITING","sponsor":"Sichuan Honghe Biotechnology Co., Ltd.","startDate":"2025-08","conditions":"Recurrent Glioblastoma","enrollment":60},{"nctId":"NCT03765918","phase":"PHASE3","title":"Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-17","conditions":"Head and Neck Neoplasms","enrollment":714},{"nctId":"NCT04380636","phase":"PHASE3","title":"Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-06","conditions":"Lung Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":870},{"nctId":"NCT06994195","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-08-04","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":384},{"nctId":"NCT05007106","phase":"PHASE2","title":"MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-16","conditions":"Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck","enrollment":613},{"nctId":"NCT05298423","phase":"PHASE3","title":"Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-05-03","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":611},{"nctId":"NCT05156970","phase":"PHASE2","title":"Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC","status":"COMPLETED","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2021-06-24","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma","enrollment":81},{"nctId":"NCT07001618","phase":"PHASE2","title":"Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-09","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer)","enrollment":162},{"nctId":"NCT06951399","phase":"PHASE2","title":"Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Rabin Medical Center","startDate":"2025-09-01","conditions":"NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IV Without EGFR/ALK Mutation, NSCLC Adenocarcinoma","enrollment":30},{"nctId":"NCT02358031","phase":"PHASE3","title":"A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-03-19","conditions":"Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer","enrollment":882},{"nctId":"NCT04624204","phase":"PHASE3","title":"Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-12-08","conditions":"Small Cell Lung Cancer","enrollment":672},{"nctId":"NCT05607550","phase":"PHASE3","title":"Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ArriVent BioPharma, Inc.","startDate":"2023-06-01","conditions":"Metastatic Non-Small Cell Lung Cancer, Advanced Non-Small Cell Lung Cancer, EGFR Exon 20 Mutations","enrollment":398},{"nctId":"NCT07009925","phase":"PHASE2","title":"Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC.","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2025-06","conditions":"Squamous Cell Lung Cancer","enrollment":38},{"nctId":"NCT06990503","phase":"PHASE3","title":"SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-01","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT04351555","phase":"PHASE3","title":"A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-16","conditions":"Non-Small Cell Lung Cancer","enrollment":358},{"nctId":"NCT04575961","phase":"PHASE2","title":"Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"North Eastern German Society of Gynaecological Oncology","startDate":"2022-02-22","conditions":"Ovarian Cancer, Low Grade Serous Carcinoma, Primary Peritoneal Carcinoma","enrollment":33},{"nctId":"NCT05825625","phase":"PHASE2","title":"NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2023-05-26","conditions":"Non-small Cell Lung Cancer","enrollment":35},{"nctId":"NCT06225284","phase":"PHASE2","title":"Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2024-08-22","conditions":"Triple Negative Breast Cancer, Premenopausal Breast Cancer","enrollment":124},{"nctId":"NCT06942416","phase":"PHASE2","title":"Iparomlimab and Tuvonralimab With Chemoradiation for the Treatment of Locally Recurrent and Oligometastatic Cervical Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2025-02-28","conditions":"Cervical Cancer, Neoplasm Recurrence, Local, Oligometastatic","enrollment":36},{"nctId":"NCT06196736","phase":"PHASE3","title":"A Study to Evaluate 9MW2821 Versus Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer","status":"RECRUITING","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2023-12-29","conditions":"Advanced Urothelial Carcinoma","enrollment":432},{"nctId":"NCT06834672","phase":"PHASE3","title":"Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2025-03-17","conditions":"Ovarian, Primary Peritoneal, Fallopian Tube Cancer","enrollment":450},{"nctId":"NCT06904573","phase":"PHASE2","title":"Probiotics in Advanced Urothelial Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-01-01","conditions":"Advanced Urothelial Carcinoma, Probiotics, Immunotherapy","enrollment":222},{"nctId":"NCT05062980","phase":"PHASE1, PHASE2","title":"Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer","status":"TERMINATED","sponsor":"Genprex, Inc.","startDate":"2022-03-30","conditions":"Non Small Cell Lung Cancer","enrollment":5},{"nctId":"NCT03777657","phase":"PHASE3","title":"Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma","status":"COMPLETED","sponsor":"BeiGene","startDate":"2018-12-13","conditions":"Gastric, or Gastroesophageal Junction Adenocarcinoma","enrollment":997},{"nctId":"NCT01828099","phase":"PHASE3","title":"LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-07-09","conditions":"Non-Small Cell Lung Cancer","enrollment":376},{"nctId":"NCT03509012","phase":"PHASE1","title":"Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-05-02","conditions":"Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma","enrollment":105},{"nctId":"NCT06751485","phase":"PHASE3","title":"JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2025-01-15","conditions":"Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancers","enrollment":430},{"nctId":"NCT03673072","phase":"PHASE3","title":"Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC","status":"COMPLETED","sponsor":"Krankenhaus Nordwest","startDate":"2019-07-01","conditions":"Incidental Gallbladder Carcinoma, Biliary Tract Cancer","enrollment":68},{"nctId":"NCT04866017","phase":"PHASE3","title":"A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"BeiGene","startDate":"2021-06-17","conditions":"Non Small Cell Lung Cancer","enrollment":63},{"nctId":"NCT03191786","phase":"PHASE3","title":"A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-09-11","conditions":"Non-Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT03598270","phase":"PHASE3","title":"Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Cáncer de Ovario","startDate":"2018-11-21","conditions":"Recurrent Ovarian Carcinoma","enrollment":417},{"nctId":"NCT03664024","phase":"PHASE2","title":"Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-30","conditions":"Non-Small Cell Lung Cancer","enrollment":118},{"nctId":"NCT06394492","phase":"PHASE3","title":"SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-05-10","conditions":"Ovarian Cancer","enrollment":440},{"nctId":"NCT06468098","phase":"PHASE1","title":"A Study of IBI363 in Subjects With Advanced Malignancies","status":"RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2024-06-15","conditions":"Advanced Malignancies","enrollment":556},{"nctId":"NCT06084897","phase":"PHASE2","title":"Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-10-16","conditions":"Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb","enrollment":120},{"nctId":"NCT01626664","phase":"PHASE2","title":"KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","startDate":"2012-06","conditions":"Adult T-cell Leukemia-Lymphoma","enrollment":71},{"nctId":"NCT02918162","phase":"PHASE2","title":"Perioperative Chemo and Pembrolizumab in Gastric Cancer","status":"COMPLETED","sponsor":"Gulam Manji","startDate":"2017-11-25","conditions":"Gastric Cancer, Adenocarcinoma of the Gastroesophageal Junction","enrollment":49},{"nctId":"NCT06211023","phase":"PHASE2, PHASE3","title":"A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2024-02-15","conditions":"Ovarian Cancer","enrollment":520},{"nctId":"NCT02657434","phase":"PHASE3","title":"A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-04-30","conditions":"Non-Small Cell Lung Cancer","enrollment":578},{"nctId":"NCT03748134","phase":"PHASE3","title":"Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2018-12-24","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":746},{"nctId":"NCT02481830","phase":"PHASE3","title":"Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-09-14","conditions":"Lung Cancer","enrollment":569}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":68,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Platinum, investigator's choice","genericName":"Platinum, investigator's choice","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Platinum compounds form DNA-damaging adducts that cross-link DNA strands, triggering apoptosis in rapidly dividing cancer cells. Used for Various solid tumors (specific indication determined by investigator choice in clinical trial).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}